DVA as reported
DaVita reported $14.0B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed.
$14.0B
Revenue, trailing twelve months · to Q2 2026 · +6.4% against the twelve months before
- Net Income
- $847M
Net Income · +1.3% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $1.61B
Free Cash Flow · +25% year on year · trailing twelve months to Q2 2026
- Op Margin
- 15%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $14.0B | +6.4% | Q2 2026 |
| Net Income | $847M | +1.3% | Q2 2026 |
| EPS | $12.15 | +20% | Q2 2026 |
| Op Margin | 15% | n/a | Q2 2026 |
| Net Margin | 6.0% | n/a | Q2 2026 |
| ROE | −116% | n/a | Q2 2026 |
| ROA | 4.5% | n/a | Q2 2026 |
| ROIC | 18% | n/a | Q2 2026 |
| Free Cash Flow | $1.61B | +25% | Q2 2026 |
| P/E | 14.8 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
DaVita (DVA) - Revenue & ProfitRevenue & ProfitDaVita (DVA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Care Facilities
Ranks #11 of 28 by Smart Score